Friday, July 15, 2011
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said that in a Phase I trial, its product VGX-3400X, a DNA vaccine, generated significant T-cell and antibody responses against avian H5N1 delivered with intramuscular electroporation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.